BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial
November 3, 2026
The company also reported early efficacy and safety data from the Phase I Breakfree-2 study
2 min read
False
Advertisement
Industry News
Off-the-Shelf CAR T Shows Early Signal in Progressive Multiple Sclerosis
November 2, 2026
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
2 min read
Amgen Expands Veeva Partnership
October 27, 2026
Global deployment of Veeva Vault CRM aims to help Amgen uncover treatment barriers and accelerate the delivery of new therapies
2 min read
Can Clinical Trials Collect Less Data Without Compromising Safety?
By Mouj Hijazi
October 22, 2026
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
5 min read
Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount
October 12, 2026
“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce
2 min read
This Month’s Manufacturing Moves
October 12, 2026
Bayer plans a $2.2 billion Ohio campus, Genentech breaks ground in Oregon, and new investments support vaccine production, downstream processing, and manufacturing in orbit
5 min read
Prula-cel Shows Early Promise in Lupus
October 8, 2026
Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy
2 min read
Building a Pre-Disease Data Map
October 7, 2026
Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear
2 min read
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read